Fractyl Health announced positive six-month results from its REMAIN-1 pivotal trial for Revita, a treatment for maintaining weight loss after GLP-1 therapy. The company plans to submit a De Novo marketing application to the FDA in late Q4 2026 and expects 12-month data in Q1 2027. To focus resources on Revita's development and commercialization, Fractyl is cutting about 45% of its workforce and discontinuing its Rejuva gene therapy program. These measures aim to reduce quarterly cash burn by 50% and extend the cash runway into Q2 2027, positioning Revita as a potential new therapy for obesity care.
Fractyl Health's recent developments on Revita provide context for readers interested in health sector trends. As of Oct 22, 2026 17:11 WIB, out of 150 priced health-sector US stocks tradable on Pluang, 66 rose and 77 fell. Notable movers include HIMS at USD 28.55 with a 1-day change of -2.26% and a typical hold time on Pluang of 22 days, ABEO at USD 4.41 down 2.22%, and MEDP at USD 648.00 down 2.19%.
Drofa Comms has released the Women Leading the Way Digital Magazine 2026, aiming to highlight women experts in finance on equal terms with men. The digital magazine features insights from 25 industry professionals and covers topics like AI in wealth ...
Fortuna Mining Corp. will announce its financial results for the third quarter of 2026 on November 4, after market close. A conference call to discuss the results will be held on November 5 at 12 p.m. Eastern time, featuring the CEO and key executive...
Gogoro Inc., a leader in battery swapping technology for electric mobility, will announce its financial results for the third quarter ending September 30, 2026, on November 11 before the market opens. The company will hold a webcast at 7 a.m. Eastern...
Aclarion's Nociscan, a noninvasive scan for diagnosing painful lumbar discs, was validated in a new study by the London Spine Clinic showing up to 87% agreement with the invasive discography procedure. Nociscan offers a safer, less painful, and more ...
The PIMCO 0-5 Year High Yield Corporate Bond Index ETF provides a relatively high 7.6% distribution yield with a portfolio focused on non-investment-grade bonds. Its shorter duration helps reduce losses amid rising interest rates, and it benefits fro...
